High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosome-negative acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 676-683

  O'Brien, Susan ^a   Schiller, Gary ^a   Lister, John ^a   Damon, Lloyd ^a   Goldberg, Stuart ^a   Aulitzky, Walter ^a   Ben Yehuda, Dina ^a   Stock, Wendy ^a   Coutre, Steven ^a   Douer, Dan ^a   Heffner, Leonard T ^a   Larson, Melissa ^a   Seiter, Karen ^a   Smith, Scott ^a   Assouline, Sarit ^a   Kuriakose, Philip ^a   Maness, Lori ^a   Nagler, Arnon ^a   Rowe, Jacob ^a   Schaich, Markus ^a   Shpilberg, Ofer ^a   Yee, Karen ^a   Schmieder, Guenter ^a   Silverman, Jeffrey A ^a   Thomas, Deborah ^a   Deitcher, Steven R ^a   Kantarjian, Hagop ^a   more..

^a Talon Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; MITOXANTRONE; NAVELBINE; VINCRISTINE SULFATE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREFLEXIA; ARTICLE; ASTHENIA; BODY WEIGHT; CANCER MORTALITY; CANCER SURVIVAL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEART ARREST; HUMAN; HYPESTHESIA; HYPOREFLEXIA; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CONSTIPATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84875716409     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.2309     Document Type: Article

References (35)

1. American Cancer Society: Cancer Facts & Figures 2012. Atlanta, GA, American Cancer Society, 2012
2. Dores GM, Devesa SS, Curtis RE, et al: Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 119:34-43, 2012
3. O'Brien S, Thomas D, Ravandi F, et al: Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113:3186-3191, 2008
4. Thomas DA, Kantarjian H, Smith TL, et al: Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy. Cancer 86: 1216-1230, 1999 (Pubitemid 29447005)
5. Tavernier E, Boiron JM, Huguet F, et al: Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907-1914, 2007 (Pubitemid 47299963)
6. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 85:2025-2037, 1995
7. Kantarjian H, Thomas D, O'Brien S, et al: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788-2801, 2004 (Pubitemid 39603187)
8. Larson S, Stock W: Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol 15:400-407, 2008
9. Welborn JL: Impact of reinduction for relapsed and refractory acute lymphoblastic leukemia in adults. Am J of Hematol 45:341-344, 1994 (Pubitemid 24109912)
10. Fielding AK, Richards SM, Chopra R, et al: Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): An MRC UKALL 12/ECOG 2993 study. Blood 109:944-950, 2007 (Pubitemid 46220637)
11. Webb MS, Harasym TO, Masin D, et al: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72:896-904, 1995
12. Krishna R, Webb MS, St Onge G, et al: Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298:1206-1212, 2001 (Pubitemid 32761941)
13. Webb MS, Logan P, Kanter PM, et al: Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42:461-470, 1998 (Pubitemid 28465209)
14. Thomas DA, Kantarjian HM, Stock W, et al: Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115:5490-5498, 2009
15. Appelbaum FR, Rosenblum D, Arceci RJ, et al: End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109:1810-1816, 2007 (Pubitemid 46348174)
16. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
17. Clopper C, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
18. US Food and Drug Administration: Center for Drug Evaluation and Research: Oncologic Drugs Advisory Committee meeting, March 21, 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugs AdvisoryCommittee/UCM304480.pdf
19. Bedikian AY, Silverman JA, Papadopoulos NE, et al: Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 51:1205-1212, 2011
20. Leonetti C, Scarsella M, Semple SC, et al: In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. Int J Cancer 110:767-774, 2004 (Pubitemid 38746037)
21. Carbone PP, Bono V, Frei E III, et al: Clinical studies with vincristine. Blood 21:640-647, 1963
22. Devita VT Jr., Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
23. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986 (Pubitemid 16028022)
24. DeVita VT Jr., Hubbard SM: Hodgkin's disease. N Engl J Med 328:560-565, 1993 (Pubitemid 23053834)
25. Carde P, MacKintosh FR, Rosenberg SA: A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1:146-153, 1983 (Pubitemid 14176804)
26. DeVita VT Jr.: The evolution of chemotherapy of lymphomas of adults. Leukemia 1:467-485, 1987 (Pubitemid 18004786)
27. Epelbaum R: Non-Hodgkin's lymphoma: Long-term survivors and adverse effects. Ann Oncol 11:123-128, 2000 (suppl 3)
28. Moore MR, Jones SE, Bull JM, et al: MOPP chemotherapy for advanced Hodgkin's disease: Prognostic factors in 81 patients. Cancer 32:52-60, 1973
29. Haim N, Epelbaum R, Ben-Shahar M, et al: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 73:2515-2519, 1994 (Pubitemid 24155527)
30. Kantarjian H, Gandhi V, Cortes J, et al: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386, 2003 (Pubitemid 37193573)
31. Cohen MH, Johnson JR, Justice R, et al: FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 13:709-714, 2008 (Pubitemid 351904915)
32. Advani AS, Gundacker HM, Sala-Torra O, et al: Southwest Oncology Group Study S0530: A phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol 151:430-434, 2010
33. Deitcher OR, O'Brien S, Deitcher SR, et al: Single-agent vincristine sulfate liposomes injection (Marqibo®) compared to historical singleagent therapy for adults with advanced, relapsed and/or refractory philadelphia chromosome negative acute lymphoblastic leukemia. Blood 118: 2592, 2011
34. Rodriguez MA, Dang N, Fayad L, et al: Phase II study of sphingosomal vincristine in CHOP -/- rituximab for patients with aggressive non-Hodgkin's lymphoma (NHL): Promising 3 year follow-up results in elderly patients. Blood 106: 943, 2005
35. Ashcroft A, Kaplan L, Damon L, et al: Sphingosomal vincristine plus rituximab for treatment of large B-cell lymphoma. Blood 102:1454, 2003